Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Circulating tumor cells in management of patients with castration-resistant prostate cancer

Giulio Francolini • 18 Feb 2022
GU Cancers 2022
Genitourinary Cancer Prostate Cancer

Giulio Francolini, MD, University of Florence, Florence, Italy, discusses how useful circulating tumor cells could be in the management of patients with castration-resistant prostate cancer. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

More from Giulio Francolini

0:27
Addition of metastasis-directed therapy in prostate cancer
Giulio Francolini • 25 Jan 2024
1:12
ARTO: local treatment in CRPC undergoing abiraterone treatment
Giulio Francolini • 25 Jan 2024
0:44
PERSIAN: apalutamide and metastases-directed SBRT in mHSPC
Giulio Francolini • 25 Jan 2024
0:31
Unmet needs in the use of circulating tumor cells for prostate cancer
Giulio Francolini • 18 Feb 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals